Prolonged DFS and reduced CNS disease recurrence in EGFR+ NSCLC under osimertinib after resection.
-
ESMO 2020 — Osimertinib is highly effective in EGFR mutation-positive resectable NSCLC -
ESMO 2020 — Expert commentary: the "evolutionary" effect of treatments on metastatic cancer Whole genome sequencing could best be performed at the diagnosis of metastatic cancer, given limited evolution.
-
World Evidence-based Healthcare Day will be held on 20 October 2020.
-
Does our attitude to medical cannabis need to change?
-
ECCVID 2020: Higher mortality in cancer patients with COVID-19 may be due to advanced age and co-morbidities Speaker said it does not appear to be the cancer itself that is leading to these poor COVID-19-related outcomes.
-
The latest stories you need to know.
-
A prospective observational cohort study of 1,171 patients with previously untreated locally advanced or metastatic colorectal cancer.
-
ECCVID 2020: Study shows 40% of healthcare workers with COVID-19 were asymptomatic One in 20 of the COVID-19-positive HCW developed severe clinical complications, and one in 200 died.
-
HER2+ breast cancer: chemo added to trastuzumab offers no benefit for older patients This trial is the first to include women in the 70-80-year age range.
-
ESMO 2020 — Is there a role for trabectedin in ovarian cancer progressing after platinum treatment? Prolonging the platinum-free interval using trabectedin after recurrence failed to improve overall survival compared to carboplatin.
-
ESMO 2020 — Towards a new combination therapy as first-line treatment in advanced renal cell carcinoma Combining nivolumab and cabozantinib leads to better survival outcomes compared to sunitinib in treatment-naïve patients with clear cell disease.
-
ESMO 2020 – Final OS analysis of abemaciclib plus tamoxifen for patients with HR+/HER2- metastatic breast cancer Finally, a MONARCH study yields proof of significanty longer survival with abemaciclib plus tamoxifen for patients with HR+/HER2- metastatic breast cancer.
-
ESMO 2020 – Prolonged survival with alpelisib+fulvestrant in HR+/HER2- advanced breast cancer with PI3K-pathway hyperactivation In patients with advanced breast cancer, targetting PIK3CA-mutations with the specific inhibitor alpelisib extends survival by 8 months.
-
A systematic review and meta-analysis of randomised controlled trials.